Skip to main content

Detection of Mu Opioid Receptor (MOPR) and Its Glycosylation in Rat and Mouse Brains by Western Blot with Anti-μC, an Affinity-Purified Polyclonal Anti-MOPR Antibody

  • Protocol
  • First Online:
Opioid Receptors

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1230))

Abstract

Our experience demonstrates that it is difficult to identify MOPR in rat and mouse brains by western blot, in part due to low abundance of the receptor and a wide relative molecular mass (Mr) range of the receptor associated with its heterogeneous glycosylation states. Here, we describe generation and purification of anti-μC (a rabbit polyclonal anti-MOPR antibody), characterization of its specificity in immunoblotting of HA-tagged MOPR expressed in a cell line, and ultimately, unequivocal detection of the MOPR in brain tissues by western blot with multiple rigorous controls. In particular, using brain tissues from MOPR knockout (K/O) mice as the negative controls allowed unambiguous identification of the MOPR band, since the anti-MOPR antibody, even after affinity purification, recognizes nonspecific protein bands. The MOPR was resolved as a faint, broad, and diffuse band with a wide Mr range of 58–84 kDa depending on brain regions and species. Upon deglycosylation to remove N-linked glycans by PNGase F (but not Endo H), the MOPR became a dense and sharp band with Mr of ~43 kDa, close to the theoretical Mr of its deduced amino acid sequences. Thus, MOPRs in rodent brains are differentially glycosylated by complex type of N-linked glycans in brain region- and species-specific manners. Furthermore, we characterized the MOPR in an A112G/N38D-MOPR knockin mouse model that possesses the equivalent substitution of the A118G/N40D SNP in the human MOPR gene. The substitution removes one of the four and five N-linked consensus glycosylation sites of the mouse and human MOPR, respectively. We demonstrated that the Mr of the MOPR in A112G mouse brains was lower than that in wild-type mouse brains, and that the difference was due to lower degrees of N-linked glycosylation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Bodei S, Arrighi N, Spano P et al (2009) Should we be cautious on the use of commercially available antibodies to dopamine receptors? Naunyn Schmiedebergs Arch Pharmacol 379:413–441

    Article  PubMed  CAS  Google Scholar 

  2. Hamdani N, van der Velden J (2009) Lack of specificity of antibodies directed against human beta-adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 379:403–407

    Article  PubMed  CAS  Google Scholar 

  3. Jensen BC, Swigart PM, Simpson PC (2009) Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific. Naunyn Schmiedebergs Arch Pharmacol 379: 409–412

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. Jositsch G, Papadakis T, Haberberger RV et al (2009) Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice. Naunyn Schmiedebergs Arch Pharmacol 379:389–395

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Lu X, Bartfai T (2009) Analyzing the validity of GalR1 and GalR2 antibodies using knockout mice. Naunyn Schmiedebergs Arch Pharmacol 379:417–420

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Michel MC, Wieland T, Tsujimoto G (2009) How reliable are G-protein-coupled receptor antibodies? Naunyn Schmiedebergs Arch Pharmacol 379:385–388

    Article  PubMed  CAS  Google Scholar 

  7. Pradidarcheep W, Stallen J, Labruyere WT et al (2009) Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 379:397–402

    Article  PubMed  CAS  Google Scholar 

  8. Huang P, Liu-Chen LY (2009) Detection of the endogenous mu opioid receptor (mopr) in brain. Front Biosci 1:220–227

    Google Scholar 

  9. Liu-Chen L-Y, Chen C, Phillips CA (1993) Beta-[3H]funaltrexamine-labeled mu-opioid receptors: species variations in molecular mass and glycosylation by complex-type, N-linked oligosaccharides. Mol Pharmacol 44:749–756

    PubMed  CAS  Google Scholar 

  10. Chen C, Xue JC, Zhu J et al (1995) Characterization of irreversible binding of beta-funaltrexamine to the cloned rat mu opioid receptor. J Biol Chem 270:17866–17870

    Article  PubMed  CAS  Google Scholar 

  11. Deng HB, Yu Y, Wang H et al (2001) Agonist-induced mu opioid receptor phosphorylation and functional desensitization in rat thalamus. Brain Res 898:204–214

    Article  PubMed  CAS  Google Scholar 

  12. Yu YK, Zhang L, Yin XX et al (1997) Mu-opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem 272: 28869–28874

    Article  PubMed  CAS  Google Scholar 

  13. Carman CV, Barak LS, Chen C et al (2000) Mutational analysis of Gbeta gamma and phospholipid interaction with G Protein-coupled receptor kinase 2. J Biol Chem 275: 10443–10452

    Article  PubMed  CAS  Google Scholar 

  14. Huang P, Xu W, Yoon SI et al (2007) Agonist treatment did not affect association of mu opioid receptors with lipid rafts and cholesterol reduction had opposite effects on the receptor-mediated signaling in rat brain and CHO cells. Brain Res 1184:46–56

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Huang P, Chen C, Xu W et al (2008) Brain region-specific N-glycosylation and lipid rafts association of the rat mu opioid receptor. Biochem Biophys Res Commun 365:82–88

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Mague SD, Isiegas C, Huang P et al (2009) Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci U S A 106: 10847–10852

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Huang P, Chen C, Mague SD et al (2012) A common single nucleotide polymorphism A118G of the mu opioid receptor alters its N-glycosylation and protein stability. Biochem J 441:379–386

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  18. Lupp A, Richter N, Dol C et al (2011) UMB-3, a novel rabbit monoclonal antibody, for assessing mu-opioid receptor expression in mouse, rat and human formalin-fixed and paraffin-embedded tissues. Regul Pept 167: 9–13

    Article  PubMed  CAS  Google Scholar 

  19. Huang P, Li J, Chen C et al (2001) Functional role of a conserved motif in TM6 of the rat mu opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp. Biochem 40: 13501–13509

    Article  CAS  Google Scholar 

  20. Schuller AG, King MA, Zhang J et al (1999) Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 2: 151–156

    Article  PubMed  CAS  Google Scholar 

  21. Mague SD, Blendy JA (2010) OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend 108:172–182

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  22. Chen C, Yin J, Riel JK et al (1996) Determination of the amino acid residue involved in [3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor. J Biol Chem 271:21422–21429

    Article  PubMed  CAS  Google Scholar 

  23. Harlow E, Lane D (1988) Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

    Google Scholar 

  24. Schagger H, von Jagow G (1987) Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 166:368–379

    Article  PubMed  CAS  Google Scholar 

  25. Xu W, Yoon SI, Huang P et al (2006) Localization of the kappa opioid receptor in lipid rafts. J Pharmacol Exp Ther 317: 1295–1306

    Article  PubMed  CAS  Google Scholar 

  26. Bergen AW, Kokoszka J, Peterson R et al (1997) Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry 2:490–494

    Article  PubMed  CAS  Google Scholar 

  27. Bond C, LaForge KS, Tian M et al (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 95: 9608–9613

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Acknowledgement

This work was supported by the National Institutes of Health (grant numbers R01 DA017302 and P30 DA013429).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lee-Yuan Liu-Chen .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this protocol

Cite this protocol

Huang, P., Chen, C., Liu-Chen, LY. (2015). Detection of Mu Opioid Receptor (MOPR) and Its Glycosylation in Rat and Mouse Brains by Western Blot with Anti-μC, an Affinity-Purified Polyclonal Anti-MOPR Antibody. In: Spampinato, S. (eds) Opioid Receptors. Methods in Molecular Biology, vol 1230. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1708-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1708-2_11

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-1707-5

  • Online ISBN: 978-1-4939-1708-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics